Table 3.
Performance of plasma immune mediators to classify leprosy patients, leprosy reactions patients, household contacts and non-infected healthy controls.
| Parameter (Cut-Off) | NI vs HHC | Parameter (Cut-Off) | L(PB) vs L(MB) | Parameter (Cut-Off) | T1LR vs T2LR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC (95%CI) | Se (95%CI) | Sp (95%CI) | AUC (95%CI) | Se (95%CI) | Sp (95%CI) | AUC (95%CI) | Se (95%CI) | Sp (95%CI) | |||
|
CXCL8
(>5.9) |
0.98
(0.9-1.0) |
100
(59-100) |
88.9
(65-98) |
CCL3
(>12.0) |
0.70
(0.5-0.9) |
53.9
(29-81) |
100
(78-100) |
IL-9
(>9.0) |
0.87
(0.7-1.0) |
72.7
(43-90) |
91.7
(65-99) |
|
CCL3
(>1.0) |
0.95
(0.9-1.0) |
100
(59-100) |
88.9
(65-98) |
CCL4 (>7.5) |
0.69 (0.5-0.9) |
92.3 (64-99) |
42.9 (18-71) |
TNF-α
(>3.1) |
0.77
(0.6-1.0) |
63.6
(31-89) |
83.3
(52-97) |
|
CCL4
(>6.8) |
0.95
(0.9-1.0) |
100
(59-100) |
77.8
(52-94) |
CCL5 (≤449.1) |
0.69 (0.5-0.9) |
76.9 (46-95) |
64.3 (35-87) |
IFN-γ
(>3.4) |
0.73
(0.5-0.9) |
54.5
(24-83) |
91.7
(62-99) |
|
TNF-α
(>2.4) |
0.90
(0.8-1.0) |
85.7
(42-98) |
94.4
(73-99) |
CXCL10 (>160.7) |
0.65 (0.4-0.9) |
92.3 (64-99) |
42.9 (18-71) |
FGF-basic
(≤1.2) |
0.71
(0.5-0.9) |
72.7
(39-94) |
66.7
(35-90) |
|
IL-1Ra
(>107.6) |
0.87
(0.7-1.0) |
85.7
(42-98) |
94.4
(73-99) |
IL-10 (≤3.44) |
0.62 (0.4-0.8) |
53.8 (25-81) |
71.4 (42-91) |
CCL4
(>15.9) |
0.70
(0.5-0.9) |
90.9
(59-99) |
58.3
(28-85) |
|
PDGF
(>107.6) |
0.87
(0.7-1.0) |
71.4
(29-96) |
100
(81-100) |
TNF-α (>1.6) |
0.60 (0.4-0.8) |
76.9 (46-95) |
50 (23-77) |
G-CSF (>22.8) |
0.67 (0.4-0.9) |
100 (71-100) |
33.3 (10-65) |
|
IFN-γ
(>2.9) |
0.82
(0.6-1.0) |
71.4
(29-96) |
100
(81-100) |
IL-17 (≤9.9) |
0.59 (0.4-0.8) |
92.3 (64-99) |
35.7 (13-65) |
CCL3 (>5.8) |
0.66 (0.4-0.9) |
90.9 (59-99) |
58.3 (28-85) |
|
G-CSF
(>44.1) |
0.79
(0.6-1.0) |
57.1
(19-90) |
94.4
(73-99) |
G-CSF (>52.0) |
0.59 (0.4-0.8) |
61.5 (32-86) |
71.4 (42-91) |
IL-4 (≤2.1) |
0.64 (0.4-0.9) |
81.8 (48-97) |
50 (21-79) |
|
IL-1β
(>0.3) |
0.78
(0.5-1.0) |
71.4
(29-96) |
94.4
(73-99) |
IL-1Ra (≤290.4) |
0.58 (0.4-0.8) |
92.3 (64-99) |
35.7 (13-65) |
CCL5 (>424.9) |
0.63 (0.4-0.9) |
77.8 (40-97) |
58.3 (28-85) |
|
IL-2
(>2.8) |
0.76
(0.5-1.0) |
57.1
(19-90) |
94.4
(73-99) |
IL-4 (≤1.3) |
0.58 (0.4-0.8) |
69.2 (39-91) |
57.1 (29-82) |
IL-1Ra (>237) |
0.61 (0.4-0.8) |
45.5 (17-77) |
83.3 (52-97) |
|
CCL5
(>552.4) |
0.74
(0.5-1.0) |
71.4
(29-96) |
88.9
(65-98) |
PDGF (≤67.7) |
0.57 (0.3-0.8) |
76.9 (46-95) |
50 (23-77) |
VEGF (>3.2) |
0.60 (0.3-0.9) |
90 (56-98) |
58.3 (28-85) |
|
IL-9
(>8.2) |
0.71
(0.5-0.9) |
57.1
(19-90) |
83.3
(59-96) |
IL-1β (≤0.1) |
0.56 (0.3-0.8) |
38.5 (14-68) |
78.6 (49-95) |
IL-1β (≤0.2) |
0.59 (0.3-0.8) |
72.7 (39-94) |
66.7 (35-90) |
| IL-12 (≤0.01) |
0.69 (0.5-0.9) |
100 (59-100) |
38.9 (17-64) |
CCL11 (≤15.7) |
0.56 (0.3-0.8) |
61.5 (32-86) |
64.3 (35-87) |
IL-13 (≤1.7) |
0.59 (0.4-0.8) |
100 (71-100) |
25 (6-57) |
| IL-6 (>0.3) |
0.67 (0.4-0.9) |
57.1 (19-90) |
77.8 (52-94) |
IL-13 (≤0.2) |
0.56 (0.3-0.8) |
38.5 (14-68) |
78.6 (49-95) |
IL-17 (>4.2) |
0.58 (0.3-0.8) |
90.9 (59-99) |
41.7 (15-72) |
| CXCL10 (>69.5) |
0.66 (0.4-0.9) |
100 (59-100) |
44.4 (22-69) |
CXCL8 (>253.5) |
0.55 (0.3-0.8) |
30.8 (9-61) |
92.9 (66-99) |
IL-5 (≤16.3) |
0.56 (0.3-0.8) |
90.9 (59-99) |
33.3 (10-65) |
| IL-17 (>7.3) |
0.64 (0.4-0.9) |
42.9 (10-81) |
88.9 (65-98) |
CCL2 (>30.7) |
0.55 (0.3-0.8) |
30.8 (9-61) |
92.9 (66-99) |
IL-6 (>0.2) |
0.56 (0.3-0.8) |
90.9 (59-99) |
33.3 (10-65) |
| IL-7 (>0.01) |
0.64 (0.4-0.9) |
85.7 (42-98) |
52.9 (28-77) |
IL-12 (≤1.8) |
0.55 (0.3-0.8) |
92.3 (64-99) |
28.6 (9-58) |
GM-CSF (≤0.8) |
0.54 (0.3-0.8) |
100 (71-100) |
16.7 (3-48) |
| IL-15 (>84.8) |
0.63 (0.4-0.9) |
28.6 (5-71) |
100 (81-100) |
FGF-basic (≤0.01) |
0.54 (0.3-0.8) |
53.8 (25-81) |
64.3 (35-87) |
IL-10 (≤11.0) |
0.53 (0.3-0.8) |
90.9 (59-99) |
25 (6-57) |
| CCL2 (>11.5) |
0.62 (0.4-0.9) |
85.7 (42-98) |
61.1 (36-83) |
IL-15 (>63.4) |
0.53 (0.3-0.8) |
53.8 (25-81) |
64.3 (35-87) |
IL-2 (>0.9) |
0.53 (0.3-0.8) |
100 (71-100) |
16.7 (3-48) |
| IL-13 (≤0.4) |
0.61 (0.3-0.9) |
71.4 (29-96) |
66.7 (41-87) |
IL-5 (≤6. 8) |
0.52 (0.3-0.8) |
53.8 (25-81) |
71.4 (42-91) |
CXCL8 (>120.5) |
0.53 (0.3-0.8) |
27.3 (6-61) |
91.7 (62-99) |
| VEGF (≤0.01) |
0.60 (0.3-0.9) |
71.4 (29-96) |
61.1 (36-83) |
IFN-γ (≤0.7) |
0.52 (0.3-0.8) |
38.5 (14-68) |
92.9 (66-99) |
CCL2 (≤6.5) |
0.53 (0.3-0.8) |
54.5 (24-83) |
75 (43-94) |
| IL-10 (≤1.0) |
0.58 (0.3-0.8) |
28.6 (5-71) |
94.4 (73-99) |
IL-6 (≤0.03) |
0.51 (0.3-0.7) |
30.8 (9-61) |
92.9 (66-99) |
CCL11 (≤44.0) |
0.52 (0.3-0.8) |
63.6 (31-89) |
50 (21-79) |
| IL-4 (≤0.9) |
0.55 (0.3-0.8) |
57.1 (19-90) |
72.2 (47-90) |
IL-2 (>3.5) |
0.51 (0.3-0.7) |
30.8 (9-61) |
85.7 (57-98) |
IL-15 (>0.01) |
0.51 (0.3-0.8) |
100 (71-100) |
25 (6-57) |
| GM-CSF (>0.28) |
0.54 (0.3-0.8) |
42.9 (10-81) |
72.2 (47-90) |
IL-7 (≤4.2) |
0.51 (0.3-0.8) |
83.3 (52-97) |
38.5 (14-68) |
PDGF (>36.5) |
0.51 (0.3-0.8) |
63.6 (31-89) |
50 (21-79) |
| FGF-basic (>4.2) |
0.54 (0.3-0.8) |
28.6 (5-71) |
83.3 (59-96) |
GM-CSF (>0.8) |
0.51 (0.3-0.7) |
15.4 (2-46) |
100 (77-100) |
IL-7 (>0.05) |
0.51 (0.3-0.8) |
81.8 (48-97) |
41.7 (15-72) |
| IL-5 (≤5.5) |
0.52 (0.2-0.8) |
57.1 (19-90) |
72.2 (47-90) |
IL-9 (>15.5) |
0.51 (0.3-0.8) |
27.3 (6-61) |
92.9 (66-99) |
CXCL10 (>348.9) |
0.51 (0.3-0.8) |
63.6 (31-89) |
50 (21-79) |
| CCL11 (≤12.6) |
0.50 (0.2-0.8) |
42.9 (10-81) |
77.8 (52-94) |
VEGF (>2.1) |
0.50 (0.3-0.7) |
83.3 (52-97) |
42.9 (18-71) |
IL-12 (>0.3) |
0.50 (0.3-0.7) |
27.3 (6-61) |
91.7 (62-99) |
*NI, Non-infected Healthy Controls; HHC, HouseHold Contacts; L(PB), Paucibacillary Leprosy Patients; L(MB), Multibacillary Leprosy Patients; T1LR, Patients with Type 1 Leprosy Reaction; T2LR, Patients with Type 2 Leprosy Reaction. Performance of soluble mediator to classify group of subjects was assessed by Receiver Operating Characteristics (ROC) curves. Global accuracy was estimated by Area Under the Curve (AUC). Sensitivity (Se) and Specificity (Sp) were determined at specific Cut-Off (expressed in pg/mL) indicated by the ROC curves. CI, confidence interval. Soluble mediators with moderate/high AUC (>0.70) are highlighted by bold underline format.